Trial
NCT01318642
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
NantBioScience, Inc.
Collaborators
—
Condition
Adenocarcinoma of the Pancreas
Intervention
Gemcitabine
Why stopped
NCT01318642: Planned independent DMC Interim review: ended for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-08